Nucleic Acid Therapeutics Market Report 2025

The nucleic acid therapeutics market size has grown rapidly in recent years. It will grow from $6.01 billion in 2024 to $6.94 billion in 2025 at a compound annual growth rate (CAGR) of 15.6%. The growth during the historic period can be attributed to the rising prevalence of genetic and chronic diseases, expanding research and development in genomics, increasing adoption of RNA-based therapeutics, enhanced support from academic and government institutions, and the growing success of mRNA vaccine platforms.

The nucleic acid therapeutics market size is expected to see rapid growth in the next few years. It will grow to $12.24 billion in 2029 at a compound annual growth rate (CAGR) of 15.2%. The growth in the forecast period can be attributed to increasing demand for precision medicine, expansion of mRNA vaccine applications beyond COVID-19, the emergence of next-generation delivery platforms, a growing pipeline of nucleic acid-based therapeutics, and rising regulatory approvals. Key trends during this period include the extension of mRNA platforms into oncology and rare diseases, integration of AI and machine learning in RNA drug discovery, development of targeted delivery systems for tissue-specific effects, modular and multi-target platform therapies, and advancements in next-generation aptamer technologies.

The rising prevalence of genetic and chronic diseases is expected to drive the growth of the nucleic acid therapeutics market in the coming years. Genetic and chronic diseases, such as diabetes, cardiovascular conditions, cancer, and autoimmune disorders, are increasingly being diagnosed due to advancements in diagnostic technologies that allow earlier and more accurate detection. Nucleic acid therapeutics provide targeted and personalized treatment options by regulating, repairing, or silencing specific genes underlying these diseases. For example, according to the Cystic Fibrosis Trust, a UK-based charity, the number of registered cystic fibrosis patients grew from 11,148 in 2022 to 11,318 in 2023, reflecting a 1.5% year-over-year increase, highlighting the growing patient population benefiting from advanced gene-targeted therapies.

Companies in the nucleic acid therapeutics market are developing innovative treatments such as antisense oligonucleotide (ASO) therapies to modulate gene expression in rare and chronic diseases. ASO therapy uses short, synthetic DNA or RNA strands to block or modify the expression of disease-causing genes, offering precision treatment. For instance, in December 2024, Ionis Pharmaceuticals Inc., a US-based biotechnology company, received FDA approval for TRYNGOLZ (olezarsen) as an adjunct therapy to diet for adults with familial chylomicronemia syndrome (FCS), a rare genetic disorder characterized by severe hypertriglyceridemia and elevated risk of acute pancreatitis. TRYNGOLZ represents the first FDA-approved therapy providing significant, sustained triglyceride reduction and a clinically meaningful decrease in acute pancreatitis incidence, administered conveniently via a once-monthly auto-injector.

In June 2025, Novartis AG, a Switzerland-based pharmaceutical company, acquired Regulus Therapeutics Inc., a US-based biotech firm specializing in microRNA-based therapies. This acquisition enhances Novartis’s capabilities in RNA-targeted drug development, strengthens its pipeline for rare and chronic disease treatments, and accelerates next-generation nucleic acid therapeutics leveraging Regulus’s expertise in microRNA modulation.

Major players in the nucleic acid therapeutics market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Novartis AG, Moderna Inc., BioNTech SE, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Imugene Limited, CureVac SE, Sangamo Therapeutics Inc., Beam Therapeutics Inc., Arbutus Biopharma Corporation, Silence Therapeutics plc, Copernicus Therapeutics Inc., and Exothera S.A.

North America was the largest region in the nucleic acid therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in nucleic acid therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the nucleic acid therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Nucleic acid therapeutics are a class of treatments that employ nucleic acids - such as deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or their synthetic analogs - to modulate gene expression or correct genetic mutations, addressing diseases at the molecular level. These therapeutics use synthetic DNA or RNA strands to target specific genetic sequences, allowing precise treatment at the molecular and genetic scale.

The primary types of nucleic acid therapeutics include antisense oligonucleotides (ASOs), small interfering RNA (siRNA), gene therapies, aptamers, and others. Antisense oligonucleotides (ASOs) are short synthetic nucleic acid strands designed to bind specific messenger RNA (mRNA) molecules, thereby blocking or altering the expression of target genes. These therapies are applied across multiple therapeutic areas, including neuromuscular, metabolic, cardiovascular, ophthalmological, and oncological disorders. Administration routes include intravenous and subcutaneous methods, and delivery systems encompass viral vector-based and non-viral approaches. Key end users include pharmaceutical companies, biotech firms, and government or academic research institutions.

The nucleic acid therapeutics market research report is one of a series of new reports that provides nucleic acid therapeutics market statistics, including the nucleic acid therapeutics industry global market size, regional shares, competitors with the nucleic acid therapeutics market share, detailed nucleic acid therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the nucleic acid therapeutics industry. This nucleic acid therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nucleic acid therapeutics market consists of revenues earned by entities by providing services such as custom oligonucleotide synthesis, gene silencing and editing services, drug discovery and development support, messenger RNA (mRNA) and small interfering RNA (siRNA) design and optimization, and delivery system development. The market value includes the value of related goods sold by the service provider or included within the service offering. The nucleic acid therapeutics market also includes sales of messenger RNA (mRNA) therapeutics, clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing tools (therapeutic use), aptamers, and Amondys 45 (casimersen). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.